PanTher Advances PTM-101 Into Expansion Phase for Non-Metastatic Pancreatic Cancer
AUSTIN, Texas | May 30, 2026 PanTher Therapeutics announced the completion of the dose-escalation portion of its Phase 1b...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
AUSTIN, Texas | May 30, 2026 PanTher Therapeutics announced the completion of the dose-escalation portion of its Phase 1b...
